RE:RE:RE:Addressable market Replying to Scarlett, I would love to believe that Trogarzo could play a role in treatment above the last ditch MDR market, but it does not seem like the study you are referring to suggests that this is what they are looking at. Clearly, the patients receiving Trogarzo will be MDR patients. Those not receiving it I am not sure about but am guessing they are also MDR patients. Perhaps you know that this trial is looking at non-MDR patients higher up the treatment scale - if so let us know that. But my long ago recollection is that Taimed and THTX never thought of Trogarzo as a drug that could adequately compete with the other treatments outside the MDR market - that was going to be the next version of Trogarzo but Taimed has focused more on drug manufacturing than drug discovery in recent years so little progress has been made on that front.
scarlet1967 wrote:
Joemare wrote: I must say it's news. It's all about the penetration rate, 25% of that market within 12-18 months.
Good news today.
They are also conducting another trial(promise) comparing heavily treated patients with and without Trogarzo. If the results are favourable that would be definitely very helpful to convince doctors and patients including Trogarzo in earlier line of treatments which is much bigger(as per company's estimates 30 plus thousand)market to penetrate.
"To compare the virologic, immunologic and clinical outcomes of patients receiving ibalizumabtreatment vs. matched patients not receiving ibalizumab."
https://clinicaltrials.gov/ct2/show/NCT05388474